Barcelona-based healthtech startup Biorce has secured €5 million (US$5.8 million) in funding from Norrsken VC, Europe’s largest impact venture capital firm.

This investment follows a €3.5 million (US$4.1 million) funding round in November 2024, led by YZR Capital and Mustard Seed Maze.

Biorce’s AI platform, Jarvis, helps fix delays and high costs in clinical trials by improving recruitment, design, and site selection.

The platform is already in use across therapeutic areas like oncology and neurology by pharma, biotech, and contract research organizations (CROs).

Since its last funding, Biorce has seen growing demand and expanded its team.

The new funds will support US sales expansion, faster product development, and growth in Spain, the UK, and the Nordics.

🔗 Source: Tech.eu

🧠 Food for thought

1️⃣ The staggering economic impact of clinical trial inefficiencies

The financial toll of clinical trial delays creates a significant market opportunity for AI solutions like Biorce’s.

Trial delays cost pharmaceutical companies between $600,000 and $8 million per day, making efficiency solutions potentially worth billions annually 1.

These costs accumulate rapidly considering that 85% of clinical trials experience delays, with most lasting between 1-6 months 2.

Patient recruitment remains the most persistent challenge, with nearly 80% of clinical trials failing to meet enrollment timelines and up to 50% of research sites enrolling one or no patients 3.

The complexity of the problem is further illustrated by the fact that 54% of phase 3 trials fail due to inadequate efficacy demonstration, while 17% fail because of safety concerns 4.

These statistics help explain why investors are eager to back solutions like Biorce that address these fundamental inefficiencies in a $84 billion market projected to reach $150 billion by 2034.

2️⃣ AI’s transformative role in clinical trial execution